Using blood samples from 200 cancer patients, researchers showed that it is possible to find most early cancer cases with targeted error correction sequencing.
Both published last month, the studies looked at, respectively, early-stage discovery of lung cancer markers and development of a clinical test for the disease.
Among its business highlights for the quarter, the firm established coverage for the Afirma genomic sequencing classifier by all major insurance plans.
Investigators using droplet digital PCR methods are following cell-free tumor DNA in the blood, looking for patterns coinciding with immunotherapy treatment outcomes.
Asia Genomics will make CellMax's tests, including the CellMax-DNA Genetic Cancer Risk Test Assure and the CellMax-CRC Protect Test, available immediately.
Neon Therapeutics is sponsoring a Phase Ib trial of neoantigen-based vaccines in combination with anti-PD-1 treatment in melanoma, lung cancer, and bladder cancer.
